Butterfly Network, Inc. (NYSE:BFLY) is among the best fundamentally strong penny stocks to buy right now. In the first quarter, Acadian Asset Management LLC raised its position in Butterfly Network, Inc. (NYSE:BFLY) by a whopping 270.5%. Following the purchase of 1,167,055 shares, the institutional investor now owns 1,598,552 shares of the company’s stock. With an ownership of 0.65%, the firm’s investment is worth $3,642,000. During its latest earnings call, the management highlighted that the second quar ...

NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between May 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased RxSight securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

公司业务与结构 - 公司是制药和医疗器械行业的主要参与者 近期市值接近4250亿美元[2] - 公司曾运营强大的消费者健康部门 生产泰诺和创可贴等知名产品 该部门于2023年分拆为独立公司Kenvue[3] 财务表现 - 第二季度收入同比增长5.8% 收益增长18%[2] - 季度股息为每股1.30美元 股息收益率为2.95%[5] 产品研发管线 - 产品组合包括免疫学治疗药物Stelara和Tremfya 以及癌症药物Darzalex和Erleada[4] - 拥有40个项目处于后期临床试验阶段 评估新候选药物并为现有治疗药物寻求额外批准[4] 股息记录 - 拥有63年股息增长记录 使其成为最佳派息股票之一[5] - 被列入12只最佳现时买入派息股票名单[1]

Two quality companies are on sale -- but only one looks like a dip worth buying right now.When great businesses sell off, investors should lean in -- but only after checking whether the fundamentals are still doing the heavy lifting. Intuitive Surgical (ISRG 0.76%), the robotic-surgery leader behind the minimally invasive da Vinci system, and The Trade Desk (TTD 1.27%), a programmatic advertising platform for the open internet, have both been under pressure this year.Both companies reported fresh quarterly ...

NEW YORK, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...

The buzz reheated Friday around a possible media mega-merger, helping lift shares of the companies involved, while a report from a short seller sent shares of a medical device manufacturer sharply low... ...

We came across a bullish thesis on Edwards Lifesciences Corporation on Natan’s Substack. In this article, we will summarize the bulls’ thesis on EW. Edwards Lifesciences Corporation's share was trading at $76.05 as of September 15th. EW’s trailing and forward P/E were 31.82 and 28.17 respectively according to Yahoo Finance. Tempus AI (TEM) Touches 7-Month High on Pixel FDA Approval Jirsak/Shutterstock.com Edwards Lifesciences, the global leader in heart valve therapies, delivered strong Q2 results that ...

Deep-pocketed investors have adopted a bearish approach towards DexCom DXCM, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DXCM usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga's options scanner highlighted 53 extraordinary options activities for DexCom. This level ...

We came across a bullish thesis on Bausch Health Companies Inc. on Countervail Capital’s Substack by Johann Colloredo-Mansfeld. In this article, we will summarize the bulls’ thesis on BHC. Bausch Health Companies Inc.'s share was trading at $7.25 as of September 11th. BHC’s trailing and forward P/E were 27.88 and 1.76 respectively according to Yahoo Finance. 25 Best Work-Life Balance Jobs to Enjoy Life Photographee.eu/Shutterstock.com Bausch Health (BHC), formerly Valeant Pharmaceuticals, is a diversifi ...

公司战略调整 - 公司为提升盈利能力决定分拆糖尿病护理业务单元 该业务是唯一面向消费者的业务且利润率较低 分拆后预计支持盈利改善 [2] - 核心业务保持稳健 作为全球最大医疗器械制造商之一 覆盖广泛治疗领域 持续开发和推出创新产品推动收入及利润稳定增长 [3] 股息表现 - 公司连续48年实现股息增长 距离成为股息之王仅差2年 [4] - 季度股息为每股071美元 股息收益率为298% 数据截至9月18日 [4] 行业地位 - 公司被列入最佳股息股票投资组合名单 [1] - 被认为是2025年股息股票投资组合的重要组成部分 [2]